ProNAi Therapeutics, Inc. (Nasdaq: DNAI) announced it has obtained an exclusive license from Carna Biosciences, Inc., Kobe, Japan, for worldwide ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE